- Home
- ALX vs AUTL Comparison
ALX vs AUTL Comparison
Compare ALX & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALX | AUTL |
|---|---|---|
| Founded | 1928 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 596.2M |
| IPO Year | 1994 | 2025 |
Fundamental Metrics
Financial Performance| Metric | ALX | AUTL |
|---|---|---|
| Price | $244.63 | $1.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 21.5K | ★ 1.6M |
| Earning Date | 05-04-2026 | 05-14-2026 |
| Dividend Yield | ★ 7.20% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 31.15 | N/A |
| Revenue | ★ $213,183,000.00 | $10,120,000.00 |
| Revenue This Year | N/A | $80.32 |
| Revenue Next Year | N/A | $53.96 |
| P/E Ratio | $7.95 | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $201.28 | $1.18 |
| 52 Week High | $289.43 | $2.58 |
Technical Indicators
Market Signals| Indicator | ALX | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 28.69 | 41.51 |
| Support Level | $243.02 | $1.37 |
| Resistance Level | $251.04 | $1.92 |
| Average True Range (ATR) | 5.31 | 0.09 |
| MACD | -1.87 | -0.05 |
| Stochastic Oscillator | 5.90 | 13.76 |
Price Performance
Historical ComparisonAbout ALX Alexander's Inc.
Alexander's Inc is a real estate investment trust engaged in leasing, managing, developing, and redeveloping its properties. It has five properties in the greater New York City metropolitan area. All of the revenues come from properties located in New York City, which include revenues from leasing of space to tenants at their properties and revenues from parking and tenant services.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.